Differential outcomes from metabolic ratios in the identification of CYP2D6 phenotypes–focus on venlafaxine and O-desmethylvenlafaxine

被引：0
|
作者：
Mani Kandasamy
P. Srinivas
Kala Subramaniam
Sandhya Ravi
James John
Radha Shekar
Nuggehally Srinivas
Saral Thangam
机构：
[1] Lotus Labs,Biometrics
[2] Lotus Labs Pvt. Ltd.,Bioanalytical
[3] Lotus Labs Pvt. Ltd.,Clinical
[4] Suramas Biopharm,Drug Development
来源：
European Journal of Clinical Pharmacology | 2010年 / 66卷
关键词：
CYP2D6; Venlafaxine; O-desmethyvenlafaxine; Pharmacokinetics; Bioavailability;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：879 / 887
页数：8
相关论文
共 50 条
  • [31] CYP2D6 Phenotyping Using Urine, Plasma, and Saliva Metabolic Ratios to Assess the Impact of CYP2D6*10 on Interindividual Variation in a Chinese Population
    Chen, Rui
    Zheng, Xin
    Hu, Pei
    FRONTIERS IN PHARMACOLOGY, 2017, 8
  • [32] Frequencies of three CYP2D6 nonfunctional alleles (CYP2D6*3,*4, and*6), and the metabolic capacity of CYP2D6 in Northern Iranian Population (Mazandaran)
    Shiran, Mohammad R.
    Soteh, Mohammad B. Hashemi
    Merat, Fatemeh
    Sarzare, Fatemeh
    Salehifar, Ebrahim
    DRUG METABOLISM REVIEWS, 2010, 42 : 260 - 261
  • [33] The Impact of CYP2D6 metabolizer phenotypes on the EDDP/methadone metabolic ratio: A comprehensive analysis
    Wilmes, Verena
    Kettner, Mattias
    Corvest, Eva
    Verhoff, Marcel A.
    Kauferstein, Silke
    FORENSIC SCIENCE INTERNATIONAL, 2025, 370
  • [34] Evaluation of the CYP2D6 Haplotype Activity Scores Based on Metabolic Ratios of 4,700 Patients Treated With Three Different CYP2D6 Substrates
    Jukic, Marin M.
    Smith, Robert L.
    Molden, Espen
    Ingelman-Sundberg, Magnus
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 110 (03) : 750 - 758
  • [35] Distribution of CYP2D6 Alleles and Phenotypes in the Brazilian Population
    Friedrich, Deise C.
    Genro, Julia P.
    Sortica, Vinicius A.
    Suarez-Kurtz, Guilherme
    de Moraes, Maria Elizabete
    Pena, Sergio D. J.
    Ribeiro dos Santos, Andrea K.
    Romano-Silva, Marco A.
    Hutz, Mara H.
    PLOS ONE, 2014, 9 (10):
  • [36] Semi-quantitative CYP2D6 gene doses in relation to metabolic ratios of psychotropics
    Hinrichs, John W. J.
    Loovers, Harriet M.
    Scholten, Bart
    van der Weide, Jan
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 64 (10) : 979 - 986
  • [37] Semi-quantitative CYP2D6 gene doses in relation to metabolic ratios of psychotropics
    John W. J. Hinrichs
    Harriët M. Loovers
    Bart Scholten
    Jan van der Weide
    European Journal of Clinical Pharmacology, 2008, 64
  • [38] Metabolic activation of zolmitriptan mediated by CYP2D6
    Han, Lingling
    Jia, Yudi
    Zhao, Yanjia
    Sun, Chen
    Zhao, Min
    Peng, Ying
    Zheng, Jiang
    XENOBIOTICA, 2021, 51 (11) : 1292 - 1302
  • [39] Pharmacokinetics of venlafaxine in subjects with extensive or poor CYP2D6 activity.
    Turgeon, J
    Lessard, E
    Yessine, MA
    Hamelin, BA
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 65 (02) : 171 - 171
  • [40] Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe
    Amchin, J
    Ereshefsky, L
    Zarycranski, W
    Taylor, K
    Albano, D
    Klockowski, PM
    JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 41 (04): : 443 - 451
12345